Skip to main content
SpringerLink
Log in

Immunoglobulin, Sepsis, and Pneumonia

  • Chapter
Management of Sepsis: The PIRO Approach

Each septic process triggers an immunological cascade which starts with the recognition and opsonisation of pathogens by an immunoglobulin, and leads finally to the destruction of the pathogens. This inflammatory process can be destructive for the host as well. Pneumonias are a particular kind of sepsis which involves specific molecules of the immune system: IgG subclasses, especially subclass 2. In every chronic, recurrent or unusual infection diagnosis of immunodeficiency should be considered. For patients who lack immunoglobulins and antibodies, intravenous substitutive immunoglobulin, given monthly and continued throughout life, is the standard of care intravenous immunoglobulins are being used as prophylaxis and treatment of sepsis and septic shock. This therapeutic use needs to be investigated more extensively in diverse septic processes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reynolds HY (1987) Host defense impairments that may lead to respiratory infections. Clin Chest Med 8(3):339–358

    PubMed  CAS  Google Scholar 

  2. Holland SM, Gallin JI (2005) Evaluation of the patient with suspected immunodefi ciency. In: Mandell GL, Bennett JE, Dolin (eds) Principles and practice of infectious diseases, 6th ed. Elsevier, Philadelphia, pp. 2–3

    Google Scholar 

  3. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolomé M, Balanzó X (2000) Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15:757–763

    Article  PubMed  CAS  Google Scholar 

  4. Woodhead M (2002) Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J (Suppl 36):20s–27s

    Google Scholar 

  5. Zilberberg MD, Exuzides A, Spalding J, Foreman A, Jones AG, Colby C, Shorr AF (2008) Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulm Med 18(8):16

    Article  Google Scholar 

  6. Donowitz GR, Mandell GL (2005) Acute pneumonia. In: Mandell GL, Bennett JE, Dolin (eds) Principles and practice of infectious diseases, 6th ed. Elsevier, Philadelphia

    Google Scholar 

  7. Feldman C, Mahomed AG, Mahida P, Morar R, Schoeman A, Mpe J, Burgin S, Kuschke RH, Wadee A (1996) IgG subclasses in previously healthy adult patients with acute community-acquired pneumonia. S Afr Med J 86(5 Suppl):600–602

    PubMed  CAS  Google Scholar 

  8. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agustí C, Angrill J, García E, Mensa J, Niederman MS, Torres A (2007) Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 132(2):515–522

    Article  PubMed  Google Scholar 

  9. Bautista MD, Bravo-Rodríguez F, Fuentes F, Sancho H (2004) Glucocorticoids and immuno-globulins in an acute respiratory distress syndrome secondary to varicella pneumoniae. Med Clin 122:238–238

    Google Scholar 

  10. Rodríguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, Palizas F (2005) Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23(4):298–304

    Article  PubMed  CAS  Google Scholar 

  11. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV (2006) A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 61(5):419–424

    Article  PubMed  CAS  Google Scholar 

  12. Ekdahl K, Braconier JH, Rollof J (1992) Recurrent pneumonia: a review of 90 adult patients. Scand J Infect Dis 24(1):71–76

    Article  PubMed  CAS  Google Scholar 

  13. Hanson LA, Söderström R, Avanzini A, Bengtsson U, Björkander J, Söderström T (1988) Immunoglobulin subclass defi ciency. Pediatr Infect Dis J 7(5 Suppl):S17–S21

    PubMed  CAS  Google Scholar 

  14. Jefferis R, Kumararatne DS (1990) Selective IgG subclass defi ciency: quantifi cation and clinical relevance. Clin Exp Immunol 81(3):357–367

    PubMed  CAS  Google Scholar 

  15. Martínez MA, Hernández FD (2000) Inmunodefi ciencias primarias y afectación pulmonar. Reuniones anuales: ponencias de la edición de 2004. Primera ponencia, parte II: infecciones y función pulmonar. http://www.alergoaragon.org/2004/primera3.html

  16. Shield JP, Strobel S, Levinsky RJ, Morgan G (1992) Immunodefi ciency presenting as hyper-gammaglobulinaemia with IgG2 subclass defi ciency. Lancet 340(8817):448–450

    Article  PubMed  CAS  Google Scholar 

  17. Ekdahl K, Braconier JH, Svanborg C (1997) Immunoglobulin defi ciencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand J Infect Dis 29(4):401–407

    Article  PubMed  CAS  Google Scholar 

  18. Heiner DC (1986) IgG subclass composition of intravenous immunoglobulin preparations: clinical relevance. Rev Infect Dis 8(Suppl 4):S391–S395

    PubMed  Google Scholar 

  19. Knutsen AP (1989) Patients with IgG subclass and/or selective antibody defi ciency to poly-saccharide antigens: initiation of a controlled clinical trial of intravenous immune globulin. J Allergy Clin Immunol 84:640–647

    Article  PubMed  CAS  Google Scholar 

  20. Morell A (1994) Clinical relevance of IgG subclass defi ciencies. Ann Biol Clin (Paris) 52(1):49–52

    CAS  Google Scholar 

  21. Spinozzi F, Cimignoli E, Gerli R, Agea E, Bertotto A, Rondoni F, Grignani F (1992) IgG subclass defi ciency and sinopulmonary bacterial infections in patients with alcoholic liver disease. Arch Int Med 152(1):99–104

    Article  CAS  Google Scholar 

  22. Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, Miravitlles M (2005) Antibody production defi ciency with normal IgG levels in bronchiectasis of unknown etiology. Chest 127(1):197–204

    Article  PubMed  CAS  Google Scholar 

  23. Ausina V, Prats G (2006) Principales grupos de seres vivos con capacidad patógena para el hombre. In: Ausina V, Moreno S (ed) Tratado SEIMC de enfermedades infecciosas y microbio-logía clínica. Editorial Médica Panamericana, Madrid

    Google Scholar 

  24. Almirall J, de Gracia J (1993–1995) Internal register, Intensive Care Unit. Hospital de Mataró, Barcelona

    Google Scholar 

  25. Francoz D, Lapointe JM, Wellemans V, Desrochers A, Caswell JL, Stott JL, Dubreuil P (2004) Immunoglobulin G2 defi ciency with transient hypogammaglobulinemia and chronic respiratory disease in a 6-month-old Holstein heifer. J Vet Diagn Invest 16(5):432–435

    PubMed  Google Scholar 

  26. Herer B, Labrousse F, MordeletQQQDambrine M, Durandy A, OffredoQQQHemmer C, Ekindjian O, Chretien J, Huchon G (1990) Selective IgG subclass defi ciencies and antibody responses to pneumococcal capsular polysaccharide antigen in adult communityQQQacquired pneumonia. Am Rev Respir Dis 142(4):854–857

    PubMed  CAS  Google Scholar 

  27. Hukuhara H, Shigeno Y, Saito A (1991) Serum levels of healthy adult humans and changes of IgG subclass levels between infected and convalescent phase in respiratory infections. Kansenshogaku Zasshi 65(5):564–570

    PubMed  CAS  Google Scholar 

  28. Söderström T, Söderström R, Andersson R, Lindberg J, Hanson LA (1988) Factors infl uencing IgG subclass levels in serum and mucosal secretions. Monogr Allergy 23:236–243

    PubMed  Google Scholar 

  29. Blasi F, Aliberti S, Allegra L, Piatti G, Tarsia P, Ossewaarde JM, Verweij V, Nijkamp FP, Folkerts G (2007) Chlamydophila pneumoniae induces a sustained airway hyperresponsiveQQQness and infl ammation in mice. Respir Res 19(8):83

    Article  CAS  Google Scholar 

  30. Bokszczanin A, Levinson AI (2003) Coexistent yellow nail syndrome and selective antibody defi ciency. Ann Allergy Asthma Immunol 91(5):496–500

    PubMed  Google Scholar 

  31. de José Gomez MI, González de Dios J, Hernando de Larramendi C, Jiménez García A, Vidal López ML, García Hortelano J (1990) IgG2 defi ciency associated with recurrent pneumonia and asthma (review of an IgG subclass). An Esp Pediatr 33(3):258–264

    PubMed  Google Scholar 

  32. Ninomiya H, Hasegawa H, Fukuoka T, Shiosaka T, Yamauchi T, Saiki O, Fujita S, Kobayashi Y (1991) Selective IgG2,4 subclass and IgE defi ciencies in an adult patient with recurrent pneumonia. Jpn J Med 30(4):339–342

    Google Scholar 

  33. Dhooge IJ, van Kempen MJ, Sanders LA, Rijkers GT (2002) Defi cient IgA and IgG2 antiQQQpneumococcal antibody levels and response to vaccination in otitis prone children. Int J Pediatr Otorhinolaryngol 17; 64(2):133–141

    Article  Google Scholar 

  34. Sorensen RU, Hidalgo H, Moore C, Leiva LE (1996) PostQQQimmunization pneumococcal antibody titers and IgG subclasses. Pediatr Pulmonol 22(3):167–173

    Article  PubMed  CAS  Google Scholar 

  35. Van Kessel DA, Horikx PE, Van Houte AJ, De Graaff CS, Van VelzenQQQBlad H, Rijkers GT (1999) Clinical and immunological evaluation of patients with mild IgG1 defi ciency. Clin Exp Immunol 118(1):102–107

    Article  PubMed  Google Scholar 

  36. Breukels MA, Rijkers GT, VoorhorstQQQOgink MM, Zegers BJ, Sanders LA (1999) Pneumococcal conjugate vaccine primes for polysaccharideQQQinducible IgG2 antibody response in children with recurrent otitis media acuta. J Infect Dis 179(5):1152–1156

    Article  PubMed  CAS  Google Scholar 

  37. Barrett DJ, Ayoub EM (1986) IgG2 subclass restriction of antibody to pneumococcal polysacQQQcharides. Clin Exp Immunol 63(1):127–134

    PubMed  CAS  Google Scholar 

  38. Sanders LA, Rijkers GT, Kuis W, TenbergenQQQMeekes AJ, de GraeffQQQMeeder BR, Hiemstra I, Zegers BJ (1993) Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections. J Allergy Clin Immunol 91(1 Pt 1):110–119

    Article  PubMed  CAS  Google Scholar 

  39. Sorensen RU, Leiva LE, Javier FC 3rd, Sacerdote DM, Bradford N, Butler B, Giangrosso PA, Moore C (1998) Infl uence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 102(2):215–221

    Article  PubMed  CAS  Google Scholar 

  40. Miravitlles M, de Gracia J, Rodrigo MJ, Cruz MJ, Vendrell M, Vidal R, Morell F (1999) Specifi c antibody response against the 23QQQvalent pneumococcal vaccine in patients with alpha(1)QQQantitrypsin defi ciency with and without bronchiectasis. Chest 116(4):946–952

    Article  PubMed  CAS  Google Scholar 

  41. Beard LJ, Ferrante A, Oxelius VA, Maxwell GM (1986) IgG subclass defi ciency in children with IgA defi ciency presenting with recurrent or severe respiratory infections. Pediatr Res 20(10):937–942

    Article  PubMed  CAS  Google Scholar 

  42. Björkander J, Bake B, Oxelius VA, Hanson LA (1985) Impaired lung function in patients with IgA defi ciency and low levels of IgG2 or IgG3. N Engl J Med 313:720–724

    PubMed  Google Scholar 

  43. De Gracia J, Vendrell M, Álvarez A, Pallisa E, Rodrigo MQQQJ, De la Rosa D, Mata F, Andreu J, Morell F (2004) Immunoglobulin therapy to control lung damage in patients with common variable immunodefi ciency. Int Immunopharmacol 6:745–753

    Google Scholar 

  44. Werdan K (2001) Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 7(5):354–361

    Article  PubMed  CAS  Google Scholar 

  45. Loh RK, Harth SC, Thong YH, Ferrante A (1990) Immunoglobulin G subclass defi ciency and predisposition to infection in Down's syndrome. Pediatr Infect Dis J 9(8):547–551

    Article  PubMed  CAS  Google Scholar 

  46. Wood P (2007) Recognition, clinical diagnosis and management of patients with primary antibody defi ciencies: a systematic review. Clin Exp Immunol Sep:149(3):410–423. Epub 2007 Jun 12. Review

    CAS  Google Scholar 

  47. Chetan G, Mahadevan S, Sulanthung K, Narayanan P (2007) Intravenous immunoglobulin therapy of lupus pneumonitis. Indian J Pediatr 74(11):1032–1033

    Article  PubMed  CAS  Google Scholar 

  48. Sakiyama Y, Komiyama A, Shiraki K, Taniguchi N, Torii S, Baba S, Yata J, Matsumoto S (1998) Intravenous immunoglobulin (GBQQQ0998) for prophylaxis of recurrent acute otitis media and lower respiratory tract infection in infancy with IgG 2 defi ciency. Nihon Rinsho Meneki Gakkai Kaishi 21(2):70–79

    PubMed  CAS  Google Scholar 

  49. Alejandria MM, Lansang MA, Dans LF, Mantaring JB (2002) Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev (1):CD001090. Review.

    Google Scholar 

  50. Laupland KB, Kirkpatrick AW, Delaney A (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and metaQQQanalysis. Crit Care Med 35(12):2686–2692

    Article  PubMed  CAS  Google Scholar 

  51. Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T (2008) HighQQQdose intravenous immunoglobulin G improves systemic infl ammation in a rat model of CLPQQQinduced sepsis. Intensive Care Med 34(10):1812–1819

    Article  PubMed  CAS  Google Scholar 

  52. Kreymann KG, de Heer G, Nierhaus A, Kluge S (2007) Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35(12):2677–2685

    Article  PubMed  CAS  Google Scholar 

  53. Leong H, Stachnik J, Bonk ME, Matuszewski KA (2008) Unlabeled uses of intravenous immune globulin. Am M HealthQQQSyst Pharm 65(19):1815–1824

    Article  CAS  Google Scholar 

  54. Provan D, Chapel HM, Sewell WA, O'Shaughnessy D, UK Immunoglobulin Expert Working Group (2008) Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 2008 (337):a1831

    Article  Google Scholar 

  55. Estrella L, Foley ME, CunninghamQQQRundles C (2007) XQQQlinked agammaglobulinemia in a 10QQQyearQQQold child: a case study. J Am Acad Nurse Pract 19(4):205–211

    Article  PubMed  Google Scholar 

  56. Dellinger RP, Levy MM, Carlet JM, et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(4):1394–1396

    Google Scholar 

  57. Fitzharris P, Hurst M (2008) Commentary: Controversies in the Department of Health's clinical guidelines for immunoglobulin use. BMJ 337:a1851

    Article  PubMed  Google Scholar 

  58. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron DW, Hébert PC (2007) MetaQQQanalysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Int Med 146(3):193–203

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Critical Care Unit, Hospital de Mataró, Universitat Autònoma de Barcelona, Ciber Enfermedades Respiratorias (CibeRes), Barcelona

    Jordi Almirall

  2. Hospital Comarcal de Blanes, Accés Cala Sant Francesc 5, Blanes (Girona), 17300, Spain

    Ester Vendrell

  3. Respiratory Intensive Care Unit Pulmonary Department, University Hospital Vall d'Hebron CIBER Enfermedades Respiratorias C/Villaroel 170, Barcelona, 08036, Spain

    Javier de Gracia

Authors
  1. Jordi Almirall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ester Vendrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier de Gracia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Intensive Care Unit, Joan XXIII University Hospital, Carrer Mallafré Guasch, 4, Tarragona, 43007, Spain

    Jordi Rello MD, PhD , Emili Díaz MD, PhD  & Alejandro Rodríguez MD, PhD ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Almirall, J., Vendrell, E., de Gracia, J. (2009). Immunoglobulin, Sepsis, and Pneumonia. In: Rello, J., Díaz, E., Rodríguez, A. (eds) Management of Sepsis: The PIRO Approach. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-00479-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-00479-7_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-00478-0

  • Online ISBN: 978-3-642-00479-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation